DE102008054127A1 - Hydrolysate of an extract of plant material comprising e.g. Equiseti herba (horsetail), Juglandis folium (walnut leaves) and Millefolii herba, obtained by hydrolytic treatment with a mineral acid, useful for treating bacterial infections - Google Patents

Abstract

Hydrolysate of at least one extract of at least one plant material comprising Equiseti herba(horsetail), Juglandis folium(walnut leaves), Millefolii herba(yarrow), Quercus cortex(oak bark), Taraxaci herba(dandelion), Althaeae radix(marshmallow root) and/or Matricariae flos(chamomile flowers), is claimed. The extract is produced by extraction of the above mentioned dried plant material. The hydrolysate is obtained from the extract by hydrolytic treatment with a mineral acid. ACTIVITY : Antibacterial; Respiratory-Gen; Dermatological. MECHANISM OF ACTION : None given.

Description

The The invention relates to a hydrolyzate of at least one extract at least one plant material selected from Equiseti herba (horsetail), Juglandis folium (walnut leaves), Millefolii herba (yarrow), Quercus cortex (oak bark), Taraxaci herba (dandelion herb), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (chamomile flowers)) or a mixture thereof and a process for the production and its use. Furthermore, the invention relates to a thereof available antibacterial agent and drug.

Imupret ^® (registered trademark of BIONORICA AG) is a known mixture of vegetable drug that is provided from these plant materials. By combining these seven medicinal plants, one obtains a composition with which one can achieve a sufficient effect for medicinal purposes. The ground crude drugs and ethanol-aqueous extracts or dry extracts produced therefrom (preparable, for example, by stripping off the solvent / extractant under reduced pressure) of the abovementioned plants have proved their worth by virtue of their exclusively herbal-based healing power. The medicinal plants used in Imupret ^® are carefully selected, examined and further processed. BIONORICA achieves the consistent quality of the drug through optimally developed breeding and harvesting strategies and the strictest quality control.

each Single drug contributes a share to the unique Effectiveness of the composition. This composition is special suitable for the treatment of respiratory infections, especially recurrent and chronic respiratory infections, preferably tonsillitis. In the Tonsillitis or synonymously angina, (tonsillo) pharyngitis, so-called tonsillitis there is an inflammation of the lymphoepithelial tissues of the lymphatic pharyngeal ring, especially the palatine tonsils. One differentiates between a.) Tonsillitis acuta: is usually caused by viruses (about 80%; Adeno, parainfluenza viruses) and beta-hemolytic streptococci Group A, less commonly caused by staph and pneumococci. The inflammation usually runs with a high fever, Sore throat, dysentery, tenderness and swelling of the submandibular lymph nodes, while reddening and swelling of the tonsils (angina catarrhalis), common individual coverings (so-called little tips) at the crypts mouths (Angina lacunaris) or via lymphoid follicles (angina follicularis, pneumococcal angina); and b.) Tonsillitis chronica: is usually due to a mixed infection with anaerobic and aerobic pathogens involving beta hemolytic Group A streptococci (by different serotypes actually New infections); pathological-anatomical retention of Cell detritus, crypt abscesses, fibrosis and necrosis of the parenchyma; Involvement of peritonsillar tissue. The inflammatory process is often relapsing. angina; minor complaints (so-called. Throat scratching), enlarged submandibular Lymph nodes, fetor ex ore, with reddened tonsils scarred and fissured surface, peritonsillar Pressure pain, with spatula pressure on the front palatal arc emptying of pus and cell detritus from the crypts.

respiratory relevant Pathogens are, for example, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae or Haemophilus influenzae. Among them is also a against methicillin resistant Staphylococcus aureus strain, called MRSA. Against this Bacterium target standard antibiotics such as beta-lactam antibiotics, For example, oxacillin, penicillin and amoxicillin, nothing more because the overuse of antibiotics, in which the pathogens are not completely killed have developed resistances. An additional Risk these germs on surgical intensive care units, where they cause pneumonia, wound infections and blood poisoning being able to lead.

There is therefore a great need the effect of Imupret ^® composition to improve and develop.

Starting from the closest prior art of the known Imupret ^® composition, it is thus an object of the present invention to provide a material which has an improved antibacterial activity.

surprisingly However, hydrolyzates of extracts from at least one show Plant drug Equiseti herba (Horsetail), Juglandis folium (Walnut leaves), Millefolii herba (yarrow), Quercus cortex (oak bark), Taraxaci herba (dandelion herb), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (Chamomile flowers)) an improved effect.

• a.) wenigstens einer der Pflanzen, ausgewählt aus der Gruppe bestehend aus: Equiseti herba (Schachtelhalmkraut), Juglandis folium (Walnussblätter), Millefolii herba (Schafgarbenkraut), Quercus cortex (Eichenrinde), Taraxaci herba (Löwenzahnkraut), Althaeae radix (Eibischwurzel) und Matricariae flos (bzw. Flos chamomillae (Kamillenblüten)); sowie einer Mischung davon; oder
• b.) einer Mischung aus: Equiseti herba (Schachtelhalmkraut), Juglandis folium (Walnussblätter), Millefolii herba (Schafgarbenkraut), Quercus cortex (Eichenrinde), Althaeae radix (Eibischwurzel) und Matricariae flos (bzw. Flos chamomillae (Kamillenblüten)); oder
• c.) einer Mischung aus: Equiseti herba (Schachtelhalmkraut), Millefolii herba (Schafgarbenkraut), Quercus cortex (Eichenrinde), Althaeae radix (Eibischwurzel) und Matricariae flos (bzw. Flos chamomillae (Kamillenblüten)); und

anschließendem Entfernen des Extraktionsmittels, wobei das Hydrolysat durch hydrolytische Behandlung mit einer Mineralsäure aus dem Extrakt erhältlich ist.In particular, the invention relates to a hydrolyzate of at least one extract which is prepared is by extraction from dried plant material:

• a.) at least one of the plants selected from the group consisting of: equiseti herba (horsetail), juglandis folium (walnut leaves), millefolii herba (yarrow), quercus cortex (oak bark), taraxaci herba (dandelion herb), althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (chamomile flowers)); and a mixture thereof; or
• b.) a mixture of: Equiseti herba (horsetail), Juglandis folium (walnut leaves), Millefolii herba (yarrow), Quercus cortex (oak bark), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (chamomile flowers)); or
• c.) a mixture of: equiseti herba (horsetail), millefolii herba (yarrow), quercus cortex (oak bark), althaeae radix (marshmallow root) and matricariae flos (or flos chamomillae (chamomile flowers)); and

subsequent removal of the extractant, wherein the hydrolyzate is obtainable by hydrolytic treatment with a mineral acid from the extract.

One preferred hydrolyzate is characterized in that the extracts by means of an extractant from 40-60 vol .-% in particular 50% by volume of ethanol and 40-60% by volume, in particular 50% by volume Water from the plant material for 24 h with stirring and then vacuum evaporation of the solvent can be produced.

A Another preferred embodiment of the invention is in a hydrolyzate which by hydrolytic treatment of the plant extracts with hydrochloric acid as a mineral acid, in particular with Hydrochloric acid of a concentration of 1 M to 10 M, preferably 6 to 9 M, in particular about 8 M at 80 degrees Celsius to 100 degrees Celsius, in particular about 90 ° C, for 30 min to 120 min, in particular 40 min to 60 min, preferably about 45 min, available is. In the final solution is the concentration the hydrochloric acid preferably 1 to 4 M, in particular 1 to 2 M, in particular 1.3 M.

It is preferred, the hydrolytic treatment of the extracts in the presence ethanol, in particular ethanol diluted with water, preferably 50% by volume of ethanol.

in the For purposes of this invention, "hydrolyzate" means a from the extract of the plant according to the invention (ndroge) aqueous phase obtained, in which the hydrolysis products are enriched. The hydrolysis is preferably carried out under the action of acid, such as hydrochloric acid, phosphoric acid, Sulfuric acid, mineral acid, in particular diluted Mineral acid. The extract can for example by a aqueous / ethanolic extract of a plant (ndroge) obtained be added by means of aqueous acid, evaporated to dryness and then in water be recorded. The hydrolysis causes the chemical cleavage of ingredients, formally a hydrogen and a hydroxide the respective fission product are added. The hydrolysis causes in the hydrolyzate, a change in the composition compared the previously known aqueous / ethanolic extracts.

In order for the hydrolysates of the present invention to be physiologically well tolerated, the extracts are concentrated to dryness after the acid treatment step, preferably taken up in water, a buffer or in dilute ethanol, and optionally neutralized with a pharmaceutically acceptable base. This comes as a base z. As NaOH, Na ₂ CO ₃ or Na ₂ HPO ₄ into consideration.

It has turned out completely surprising that the hydrolysates according to the invention an antibacterial Have effect.

The Hydrolyzates of the present invention generally have a significant antibacterial effect, which in their range of action with an antibiotic control of amoxicillin and clavulanic acid (Mass ratio 6: 1) is comparable.

The Hydrolysates of the present invention may be used are used to produce antibacterial agents Respiratory bacteria, especially Gram-positive cocci, in particular Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans and / or Gram-negative rod bacteria, in particular Haemophilus influenzae and / or MRSA (methicillin-resistant Staphylococcus aureus).

The hydrolysates were tested in the context of the present invention against the following pathogens relevant to the ENT and respiratory tract and found to be effective: Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), Streptococcus pneumoniae (DSMZ 20566), Streptococcus pyogenes (DSMZ 20565), Streptococcus mutans (ATCC 35668), Haemophilus influenzae (DSMZ 4690), Klebsiella pneumoniae (ATCC 13883), and Enterococcus casseliflavus (VRE) (DSMZ 20680 ) and against the intestinal bacteria Escherichia coli (ATCC 25922), Enterococcus faecalis (VRE) (ATCC 19433).

In advantageous and known per se, the hydrolysates the present invention for the preparation of an antibacterial To be used by means. Such antibacterial agents can for the protection and / or treatment of infections orally or topically on skin and mucous membranes, palate in the form of one of her Application appropriate galenic formulation can be used.

The galenic formulations of hydrolyzates / antibacterial agents The present invention is characterized in that oral formulations such as dragees, tablets, film-coated tablets, powders, capsules or liquid dilutions, in particular drops, Juices or syrups include.

at Use for topical application are in particular sprays, Ointments, emulsions, powders, powders, liquid or solid Preparations for inhalation, compresses, wound care and gum deposits, tamponades, tonsillar brush solutions, Gurgell solutions or rinsing solutions for Nose and ear. The above mentioned tamponades are also suitable for dental applications.

to Use of the hydrolysates according to the invention as Rinse solutions for nose and ear are these are beneficial in combination with physiological or hyperosmolar ones Concentrations of salts or salt mixtures used. For the use as an antibacterial agent has been found that a preparation present as a lyophilisate has many advantages has, namely in storage and long-term stability. The antibacterial agents of the present invention can of course the usual pharmaceutical Excipients included.

In microbiological studies at the Institute of Hygeny at the Medical University of Innsbruck has surprisingly been found that the hydrolysates of the invention show a broad, sometimes pronounced antibacterial effect against skin, respiratory and ENT-relevant pathogens, which in relevant tests on their antibacterial effect considerably were more pronounced than was the case with unhydrolysed extracts. For example, in antibacterial susceptibility tests with the Aggler diffusion test according to Mueller-Hinton ( Mueller, HJ and Hinton, J. (1941): A protein-free medium for primary isolation of the gonococcus and meningococcus. Proc. Soc. Expt. Biol. Med .; 48: 330-333 ) that of the seven hydrolysed individual drug extracts, the hydrolysates according to the invention against several pathogens were effective and the majority of unhydrolyzed mixture surprisingly showed in the agar diffusion test virtually no antibacterial activity against the tested bacterial reference panel.

The However, it is the biggest surprise that a hydrolyzate of a mixture of Equiseti herba (horsetail), Juglandis folium (walnut leaves), Millefolii herba (yarrow), Quercus cortex (oak bark), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (chamomile flowers)) or Equiseti herba (Horsetail herb), Millefolii herba (Yarrow herb), Quercus cortex (oak bark), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (chamomile flowers)) a significant antibacterial activity against all shows tested bacterial strains.

Essential In addition, this antibacterial activity is the known anti-inflammatory Effectiveness complements and therefore the pallative and curative Effect of the composition of the plants according to the invention (drugs) improved, even in a 7 or 6 combination.

The hydrolysates and antibacterial agent of the present invention can thus be used to advantage in the treatment of pathogen-related infections. The anti-inflammatory effect of the studied drugs and drug mixtures is supplemented by the additional antibacterial effect, which completely stops a respiratory infection by killing the bacterial pathogens. Through the medicinal uses of the seven medicinal plants, Equiseti herba, Juglandis folium, Millefolii herba, Quercus cortex, Taraxaci herba, Althaea radix and Matricariae flos (or Flos chamomillae (chamomile flowers)), a patient affected by tonsillitis is gently treated without synthetic chemical components. The preparation is also characterized by a good compatibility with regard to its interactions with other drugs and in view of the rare side effects. The antibacterial agent of the present invention is particularly effective against the following pathogens, especially against gram-positive coke ken as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, and Klebsiella against gram-negative rod bacteria such as Haemophilus influenzae, Pseudomonas aeruginosa and against Enterobacteriaceae faecalis (VRE), Enterobacteriaceae casseliflavus and E. coli shows antibacterial activity. Thus, the present invention also relates to the use of the hydrolysates and antibacterial agents according to the invention for the manufacture of a medicament for the treatment of respiratory tract and ENT infections caused by respiratory tract and ENT-relevant pathogens.

In In another embodiment, the invention relates to a Process for the preparation of hydrolysates, available from at least one aqueous / ethanolic extract at least one plant (ndroge) Equiseti herba (horsetail), Juglandis folium (walnut leaves), Millefolii herba (yarrow), Quercus cortex (oak bark), Taraxaci herba (dandelion herb), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (Chamomile flowers)), preferably an aqueous / ethanolic Extract is mixed with aqueous acid and then collected the soluble fractions be (= hydrolyzate).

The The invention also relates to a process for the preparation of a antibacterial agent, whereby from at least one plant (ndroge) selected from Equiseti herba (Horsetail), Juglandis folium (walnut leaves), millefolii herba (yarrow), Quercus cortex (oak bark), Taraxaci herba (dandelion herb), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (Chamomile flowers)) in a first step, preferably aqueous / ethanolic Extract is produced and obtained in a second step Extract is mixed with an aqueous acid and the aqueous fractions collected and optionally dried become.

In a further embodiment of the invention the resulting hydrolysates are converted to a dry mass become. In a preferred embodiment, a Freeze-drying of the hydrolysates carried out. Other drying methods However, they are also usable.

Either the hydrolysates of the invention as well as their aqueous suspensions, dry masses show an antibacterial Effect. Therefore, the invention relates to a corresponding antibacterial Agent or the use of the invention Hydrolysates as antibacterial agent.

The The invention also relates to a medicament consisting of a hydrolyzate according to the invention of said plants (drugs), as described above, or dry matter or an antibacterial according to the invention Means for the treatment of respiratory infections or the use the antibacterial agents according to the invention as a medicine.

Of the Term "respiratory infections" includes all Forms of inflammation and / or respiratory infections caused by bacteria, especially tonsillitis. "Airway" means the respiratory tract to the alveoli; the upper respiratory tract include the nasal cavity with its sinuses and the throat, where the airway crosses the food path. The lower respiratory tract begins with the larynx, followed by the trachea including the entire branching of the bronchial tree.

Further The invention relates to a pharmaceutical formulation containing an inventive drug or antibacterial Medium.

The Antibacterial agents can be in the form of pharmaceutical Preparations are prepared in dosage units. This means, that the preparation in the form of individual parts, for. As tablets, dragees, capsules, Pills, suppositories and ampoules are present whose active ingredient content a fraction or a multiple of a single dose. The dosage units can z. B. 1, 2, 3 or 4 single doses or 1/2, 1/3 or 1/4 of a single dose. A single dose contains preferably the amount of active ingredient in a Application is administered and usually one whole, a half, a third or a quarter of a daily dose equivalent.

Under non-toxic, inert pharmaceutically acceptable excipients are solid, semi-solid or liquid diluents, To understand fillers and formulation aids of any kind.

Preferred pharmaceutical formulations are tablets, dragees, capsules, pills, granules, suppositories, solutions, juice, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and (nasal) sprays. Tablets, dragees, capsules, pills and granules may contain the active ingredient (s) in addition to the usual excipients, such as a) fillers and extenders, e.g. As starches, lactose, cane sugar, glucose, mannitol and silica, b) binders, for. Carboxymethylcellulose, alginates, Gelatin, polyvinylpyrrolidone, c) humectants, e.g. Glycerol, d) disintegrants, e.g. Agar agar, calcium carbonate and sodium carbonate, e) solution retarder, e.g. Paraffin and f) resorption accelerators, e.g. G., Quaternary ammonium compounds, g) wetting agents, e.g. Cetyl alcohol, glycerol monostearate, h) adsorbents, e.g. Kaolin and bentonite and i) lubricants, e.g. As talc, calcium and magnesium stearate and solid polyethylene glycols or mixtures of the substances listed under a) to i).

The Tablets, dragees, capsules, pills and granules can with the usual, optionally Opakisierungsmittel containing coatings and envelopes and be composed in this way, that they or the active ingredients only or preferably in one may delay certain part of the intestinal tract leave as embedding masses z. B. Polymer substances and Waxes can be used. The active substance (s) Optionally, use one or more of the above specified carriers also in microencapsulated form available.

suppositories can in addition to the active substance or the usual water-soluble or water-insoluble excipients included, for. As polyethylene glycols, fats, z. B. cocoa fat and higher esters (eg C14-alcohol with C16-fatty acid) or mixtures of these substances.

Anoint, Pastes, creams and gels may be next to the active ingredient (s) contain the usual carriers, for. B. animal and vegetable fats, waxes, paraffins, starch, tragacanth cellulosics, Polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.

powder and sprays may, in addition to the active substance or the usual Carriers contain, for. Lactose, talc, silicic acid, Aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays can also use the usual Propellant included.

solutions and emulsions may in addition to the active substance or the usual Carriers such as solvents, solubilizers and emulsifiers, e.g. Water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, Benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, Dimethylformamide, oils, in particular cottonseed oil, Peanut oil, corn oil, olive oil, Castor oil and sesame oil, glycerol, glycerol formal, tetrahydrofurfuryl alcohol, Polyethylene glycols and fatty acid esters of sorbitan or Mixtures of these substances included.

suspensions can in addition to the active substance or the usual Carriers such as liquid diluents, z. For example, water, ethyl alcohol, propylene glycol, suspending agent, z. B. ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances. The mentioned Formulations may also include colorants, preservatives as well as odor and taste-improving additives, eg. B. Peppermint oil and eucalyptus oil and sweeteners, z. For example, saccharin.

For the preparation of the extracts according to the invention and their combinations from the plants is based on the technical teachings, the subject of EP 1368605B1 . EP 0753306B1 are directed.

Further Advantages and features of the present invention are due to the description of embodiments. The following Examples serve to illustrate the invention without the To limit the invention to these examples.

Examples:

Preparation of the test solutions

The Individual drugs as well as mixed extracts with variable drug composition (7-plant extract and less) were dissolved in 50% EtOH / H2O (v / v, ca. 1 g of plant material to 20 ml of solvent) for Extracted with stirring at room temperature for 24 h. 1.6 ml Extract was mixed with 320 μl of 25% HCl (equivalent to 8.1 mol / L). and 80 μl of 50% EtOH and 45 minutes hydrolyzed at 90 ° C. For comparison, in a second Step the hydrolysis with 1 ml of extract with the addition of 1 ml 25% HCl was carried out under the same conditions. After evaporation of the extracts, the residue was dissolved in 1 ml of sterile water recorded and tested for their antibacterial effect.

Screening Procedure: 80 μl of test solution was applied to Mueller Hinton Agar plates or Mueller Hinton agar plates containing 5% mutton blood containing an unknown concentration of the bacteria to be tested carried and incubated at 37 ° C for 24 h.

Spiral Platter: A bacterial colony was suspended in 5 ml of CASO-Boullon and incubated at 37 ° C for 24 h. The supernatant was removed after centrifuging the sample, washed with 0.9% NaCl and diluted to a concentration of 10 ⁷ cfu / ml (colony forming unit per milliliter). The test solutions were diluted 1: 2, 1:20 and 1: 200 and mixed with the bacterial suspension (for Pneumococcus and H. influenzae: 1:10, for the remaining pathogens 1: 100). The positive control used was 0.9% NaCl. The samples were plated with a Whitley Automatic Spiral Platter (WASP) at 0, 4 and 8 hours and incubated at 37 ° C for 24 hours.

Out Table 1 shows that in comparison of the unhydrolyzed and hydrolyzed extracts show especially the hydrolysates of Equiseti herba, Matricariae flos and Millefolii herba a distinct Increased antibacterial effect, being the non-hydrolyzed Extracts were not or were little active. By the hydrolysis of the extract Quercus cortex can increase the antibacterial effect from 7 to 10 Pathogens are expanded while Juglandis folium a has little antibacterial effect by the hydrolysis. Althaeae radix has an increased antibacterial effect through hydrolysis against pneumococcus and H. influenzae.

QUOTES INCLUDE IN THE DESCRIPTION

This list The documents listed by the applicant have been automated generated and is solely for better information recorded by the reader. The list is not part of the German Patent or utility model application. The DPMA takes over no liability for any errors or omissions.

Cited patent literature

• - EP 1368605 B1 [0042]
• EP 0753306 B1 [0042]

Cited non-patent literature

• - Mueller, HJ and Hinton, J. (1941): A protein-free medium for primary isolation of the gonococcus and meningococcus. Proc. Soc. Expt. Biol. Med .; 48: 330-333 [0022]

Claims (10)

A hydrolyzate of at least one extract prepared by extraction from dried plant material of: a.) At least one of the plants selected from the group consisting of: equiseti herba (horsetail), juglandis folium (walnut leaves), millefolii herba (yarrow), quercus cortex (oak bark), Taraxaci herba (dandelion herb), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (chamomile flowers)); and a mixture thereof; or b.) a mixture of: Equiseti herba (horsetail), Juglandis folium (walnut leaves), Millefolii herba (yarrow), Quercus cortex (oak bark), Althaeae radix (marshmallow root) and Matricariae flos (or Flos chamomillae (chamomile flowers)); or c.) a mixture of: equiseti herba (horsetail), millefolii herba (yarrow), quercus cortex (oak bark), althaeae radix (marshmallow root) and matricariae flos (or flos chamomillae (chamomile flowers)); and subsequently removing the extractant, characterized in that the hydrolyzate is obtainable by hydrolytic treatment with a mineral acid from the extract. Hydrolyzate according to claim 1, characterized in that that the extracts by means of an extractant from 40-60 Vol .-% ethanol and 40-60 vol .-% of water from the plant material on 6 to 36 h, in particular 12 to 30 h, with stirring and if necessary. Vacuum evaporation of the solvent can be produced. Hydrolyzate according to Claim 1 or 2, characterized that by hydrolytic treatment of the extracts with hydrochloric acid as a mineral acid, in particular a concentration of 1M to 10M, especially 6M to 9M, at 80-100 degrees Celsius, for 30 to 120 min., In particular 40 to 60 min. is available and / or the final solution a concentration the hydrochloric acid of 1 to 4 M, in particular 1 to 2 M, in particular 1.3 M has. Hydrolyzate according to one of the preceding claims, characterized in that the hydrolyzate has an antibacterial Has effect. Hydrolyzate according to one of the preceding claims, characterized in that the hydrolyzate in a dry mass or aqueous suspension is present, optionally neutralized is. Hydrolyzate according to one of the preceding claims, characterized in that the antibacterial effect in comparison to the non-hydrolytically treated pure plant drugs in theirs Effective width with antibiotic control of amoxicillin and clavulanic acid (Mass ratio 6: 1) is comparable. Hydrolyzate according to one of the preceding claims, characterized in that the antibacterial activity against skin, ENT and respiratory relevant bacteria, especially Gram positive Cocci, in particular Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans and / or Gram-negative rod bacteria, in particular Haemophilus influenzae, and / or MRSA (methicillin-resistant Staphylococcus aureus). Hydrolyzate according to one of the preceding claims, characterized in that it is in a galenic formulation especially an oral formulation such as dragees, tablets, Film-coated tablets, capsules, liquid dilutions, especially drops, juices, syrups or a formulation for topical use such as sprays, ointments, emulsions, powders, powders, liquid or solid preparations for the Inhalation, compresses, wound and gum deposits, tamponades, Tonsil brush solutions, gargles or rinsing solutions for nose and ear or lyophilisate. Antibacterial agent containing a hydrolyzate according to one of claims 1 to 8. A pharmaceutical composition comprising an antibacterial agent according to claim 9 for the prophylaxis and treatment of respiratory infections, especially tonsillitis.